Most of the bills discussed during the markup session received bipartisan support, reflecting a shared commitment to improving veterans' care and addressing the needs of this population.

Representative Bergman introduced HR 6373, the Veteran Spinal Trauma Access to New Devices or Veteran Stand Act, which would codify existing VA policy regarding the provision of assistive technology for veterans with spinal cord injuries. The bill received strong bipartisan support, with members emphasizing the need to improve access to assistive devices and ensure that veterans are able to receive the care they need.

Representative DeLusio introduced HR 3225, the Build for Veterans Act, which aims to improve VA's capital asset management planning and investment processes. This bill received strong bipartisan support, with members emphasizing the need to address the VA's backlog of infrastructure projects and ensure more efficient use of resources.

Representative Brownley expressed strong opposition to HR 3649, citing concerns that the scientific literature does not support HBOT as a clinically indicated treatment for PTSD and TBI. She also raised concerns about the bill's funding mechanism and potential negative impacts on VA resources and program administration.

Representative Murphy introduced HR 3649, the Veterans National Traumatic Brain Injury Treatment Act, which would require the VA to implement a pilot program for HBOT treatment for veterans with traumatic brain injuries and PTSD. The bill received bipartisan support, with several members emphasizing the potential benefits of HBOT for veterans struggling with these conditions, citing anecdotal evidence and the need for alternative treatment options.

The committee members acknowledged the concerns raised at a previous legislative hearing and indicated a willingness to work with the VA and other stakeholders to address these concerns and amend legislation as necessary.

The markup session highlighted the importance of the VA's role in implementing legislation and ensuring that veterans receive timely and effective care. Several members expressed concerns about the VA's response to some of the proposed legislation, suggesting a need for increased oversight and accountability.

Representative Van Orton introduced HR 7347, which would require the VA to make a formulary determination for psychedelic therapies within six months of FDA approval. This bill received bipartisan support, with members highlighting the potential benefits of psychedelic therapies for veterans struggling with mental health conditions and emphasizing the need to explore alternative treatment options.

Several members, including Representative Van Orton, stressed the urgency of addressing the veteran suicide crisis and exploring alternative treatment options, including psychedelic therapies, to prevent further suicides.

Representative Van Orton criticized the VA's opposition to HR 4424, which would require a study on the potential link between liver flu cancer and Agent Orange exposure in Vietnam veterans. He expressed concern that the VA was unwilling to address potential health risks for veterans due to regulatory concerns.

The committee approved 10 lease resolutions for VA facilities, enabling the VA to acquire or renovate facilities for clinical and research purposes. This action was seen as a positive step towards improving access to VA services for veterans.

An amendment in the nature of a substitute was adopted for HR 3644, extending the authorization period for emergency treatment of veterans at non-VA facilities and codifying a 96-hour window for emergency treatment.

Representative Brownley expressed concerns regarding the $75 million funding request for HR 3303, the Maternal Health for Veterans Act, questioning the need for additional funding given ongoing VA efforts in this area and the overall increase in the women's veteran health budget. She indicated a willingness to work with the committee to address these concerns.